Neuroscience
From FierceBiotech:
Merck KGaA pulls ahead in hot oral MS drug race
By John Carroll
September 11, 2009 — 8:22am ET
Researchers for Merck KGaA say that new analysis of the late-stage data for their oral drug cladribine highlight the drug's potential as a new therapy for multiple sclerosis. Patients taking a short course of the therapy were more likely to go two years without seeing the disease flare up, and that could prove crucial for the developer as it prepares to make its case that cladribine should be neurologists' preferred choice among a slate of experimental oral MS therapies.
Read the full article
- Fda Approves Multiple Sclerosis Drug, Ampyra (dalfampridine) Extended-release
From FierceBiotech: FDA approves Acorda's new MS drug January 22, 2010 — 4:49pm ET By John Carroll [snip] The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with...
- Business World: Novartis, Multiple Sclerosis, Fty720, & Betaseron
From The Wall Street Journal's Health Blog: AUGUST 17, 2009, 11:12 AM ET Novartis’s Big Plans for Multiple Sclerosis By Jeanne Whalen [snippet] The FDA gave Novartis the green light today to start selling a copy of Betaseron, the multiple sclerosis...
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Business World: Emd 281014 And Insomnia
From the New York Times website: Lilly to Buy Insomnia Compound By THE ASSOCIATED PRESS Published: October 28, 2004 Filed at 11:21 a.m. ET INDIANAPOLIS (AP) -- Eli Lilly and Co. will pay a German pharmaceutical company $29 million for the...
- Pharmaceutical Clinical Trials: Merck
From The New York Times (06 September 2004; free registration required): Merck Says It Will Post the Results of All Drug Trials By GARDINER HARRIS Merck & Company says it will post the results of its clinical trials on drugs on a Web site run by...
Neuroscience
Merck's Cladribine and Multiple Sclerosis
From FierceBiotech:
Merck KGaA pulls ahead in hot oral MS drug race
By John Carroll
September 11, 2009 — 8:22am ET
Researchers for Merck KGaA say that new analysis of the late-stage data for their oral drug cladribine highlight the drug's potential as a new therapy for multiple sclerosis. Patients taking a short course of the therapy were more likely to go two years without seeing the disease flare up, and that could prove crucial for the developer as it prepares to make its case that cladribine should be neurologists' preferred choice among a slate of experimental oral MS therapies.
Read the full article
- Fda Approves Multiple Sclerosis Drug, Ampyra (dalfampridine) Extended-release
From FierceBiotech: FDA approves Acorda's new MS drug January 22, 2010 — 4:49pm ET By John Carroll [snip] The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with...
- Business World: Novartis, Multiple Sclerosis, Fty720, & Betaseron
From The Wall Street Journal's Health Blog: AUGUST 17, 2009, 11:12 AM ET Novartis’s Big Plans for Multiple Sclerosis By Jeanne Whalen [snippet] The FDA gave Novartis the green light today to start selling a copy of Betaseron, the multiple sclerosis...
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Business World: Emd 281014 And Insomnia
From the New York Times website: Lilly to Buy Insomnia Compound By THE ASSOCIATED PRESS Published: October 28, 2004 Filed at 11:21 a.m. ET INDIANAPOLIS (AP) -- Eli Lilly and Co. will pay a German pharmaceutical company $29 million for the...
- Pharmaceutical Clinical Trials: Merck
From The New York Times (06 September 2004; free registration required): Merck Says It Will Post the Results of All Drug Trials By GARDINER HARRIS Merck & Company says it will post the results of its clinical trials on drugs on a Web site run by...